55 patienter fik 50 mg og den anbefalede behandlingscyklus på 4 på hinanden følgende uger og 2 uger uden behandling (doseringsskema 4/ 2).
Ninety-seven patients were enrolled at various doses and schedules; 55 patients received 50 mg at the recommended treatment schedule 4 weeks on / 2 weeks off (“ schedule 4/ 2”).